Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.
MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.
MiRXES Pte. Ltd., founded in 2014 and based in Singapore, specializes in life science research tools and molecular diagnostic tests for both research and clinical applications. The company has developed a leading microRNA (miRNA) detection assay platform designed to identify cancer at asymptomatic stages. Its product offerings include RT-qPCR assays, assay panels, spike-in RNA kits, and solutions for biomarker discovery. By focusing on early cancer detection, MiRXES provides healthcare professionals with essential diagnostic tools to improve clinical outcomes through timely intervention.
EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in developing, manufacturing, and promoting cell-based immunotherapies aimed at treating cancer. The company leverages advanced technologies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies, to enhance the body's immune response against cancer. JW Therapeutics focuses on addressing both hematological cancers and solid tumors, with its leading product candidate being relmacabtagene autoleucel, designed as a potential superior anti-CD19 CAR-T therapy. The company's mission is to improve patient outcomes and quality of life for those battling cancer through innovative treatment solutions.
Genor BioPharma Co., Ltd. is a biopharmaceutical company based in Shanghai, China, founded in 2007. It specializes in the development and commercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusion protein drugs, focusing primarily on oncology, autoimmune diseases, and metabolic disorders. The company aims to address significant unmet medical needs through its pipeline, which includes more than ten products, with several already in clinical development. Notable candidates include GB491, an oral CDK4/6 inhibitor; GB221, a novel HER2 mAb; geptanolimab (GB226); and GB242, an infliximab biosimilar. Genor BioPharma also collaborates strategically with Ascentage Pharma to enhance its research and development efforts.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
CF PharmTech, Inc. is a specialty pharmaceutical company based in Suzhou, China, focused on the development and manufacturing of inhalation products for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Founded in 2007, the company offers a range of products including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. In addition to its product offerings, CF PharmTech provides contract manufacturing organization (CMO) services and is actively involved in research and development in its specialized field. The company aims to provide high-quality and affordable medicines to enhance patient care and management of respiratory conditions, catering to a global market. Its headquarters are strategically located in the Caohu District, ensuring convenient transportation access to major cities like Shanghai and Beijing.
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for critical human diseases through RNA interference (RNAi) technologies. The company focuses on oncology, anti-fibrotic treatments, and viral infections, leveraging its proprietary Polypeptide Nano-Particle (PNP) technology for effective small interfering RNA (siRNA) drug delivery. Sirnaomics has several product candidates, including STP705 for scar reduction and liver fibrosis, STP909 for colon cancer, and STP602 for Zika virus. Founded in 2007, the company operates from its headquarters in Gaithersburg, Maryland, with additional facilities in Cambridge, Massachusetts, and China. Sirnaomics is strategically partnered with Precision NanoSystems Inc. to enhance its development capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.